{
  "meta": {
    "title": "47_Corticosteroids",
    "url": "https://brainandscalpel.vercel.app/47-corticosteroids-b65f7e90.html",
    "scrapedAt": "2025-11-30T12:34:29.862Z"
  },
  "questions": [
    {
      "text": "Glucocorticoids act on which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "G protein couple receptor"
        },
        {
          "id": 2,
          "text": "Intracellular cytoplasmic receptor"
        },
        {
          "id": 3,
          "text": "Ligand gated ion channel"
        },
        {
          "id": 4,
          "text": "JAK-STAT pathway"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Glucocorticoids</strong> act on the intracellular <strong>cytoplasmic receptors.&nbsp;</strong></p>\n<p>They diffuse into cytosol and bind to the cytoplasmic receptors and influence nuclear changes by activation of the receptor.&nbsp;</p><hr><h3>Related Pearl: Mechanisms of Action of Hormones</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Types of hormone receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to intracellular receptors</strong></td>\n</tr>\n<tr>\n<td rowspan=\"3\">Cytoplasmic receptors</td>\n<td>Glucocorticoids</td>\n</tr>\n<tr>\n<td>Mineralocorticoids</td>\n</tr>\n<tr>\n<td>Androgens</td>\n</tr>\n<tr>\n<td> </td>\n<td>Vitamin D</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Nuclear receptors</td>\n<td>Thyroid hormones</td>\n</tr>\n<tr>\n<td>Vitamins A</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to cell surface receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\">1. <strong>G-protein coupled receptors</strong> (GPCR)</td>\n</tr>\n<tr>\n<td rowspan=\"9\"><strong>Gs</strong>: stimulation of second messenger cAMP</td>\n<td>ACTH, CRH</td>\n</tr>\n<tr>\n<td>TSH, GHRH</td>\n</tr>\n<tr>\n<td>FSH, LH, hCG</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Catecholamines (β receptors)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td>Glucagon</td>\n</tr>\n<tr>\n<td>Secretin</td>\n</tr>\n<tr>\n<td>Parathyroid hormone</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>Gi: </strong>inhibition of second messenger cAMP</td>\n<td>Catecholamines (ɑ<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Acetylcholine (M2, M4)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td rowspan=\"11\">\n<p><strong>Gq</strong>: second messenger is phospholipase C or cGMP</p>\n</td>\n<td><strong>Phospholipase C (IP3 DAG pathway):</strong></td>\n</tr>\n<tr>\n<td>GnRH, GHRH, TRH</td>\n</tr>\n<tr>\n<td>Catecholamines (ɑ<sub>1</sub> receptors)</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>1</sub> receptor)</td>\n</tr>\n<tr>\n<td>Gastrin</td>\n</tr>\n<tr>\n<td>Cholecystokinin</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td>Acetylcholine (M1, M3, M5)</td>\n</tr>\n<tr>\n<td><strong>cGMP:</strong></td>\n</tr>\n<tr>\n<td>Atrial natriuretic peptide</td>\n</tr>\n<tr>\n<td>Nitric oxide</td>\n</tr>\n<tr>\n<td colspan=\"2\">2. <strong>Tyrosine kinase</strong> receptors</td>\n</tr>\n<tr>\n<td rowspan=\"5\">Through the <strong>JAK-STAT</strong> (non-receptor tyrosine kinase) or <strong>MAP kinase</strong> (receptor tyrosine kinase) pathway </td>\n<td>Growth factors like IGF, VEGF, FGF, PDGF</td>\n</tr>\n<tr>\n<td>Growth hormone</td>\n</tr>\n<tr>\n<td>Erythropoietin</td>\n</tr>\n<tr>\n<td>Insulin</td>\n</tr>\n<tr>\n<td>Prolactin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Notes: <br />1. Even though the cytoplasmic receptors are present in the cytoplasm, once the <strong>hormone-receptor complex</strong> is formed it moves to the <strong>nucleus</strong> for its actions.</p>\n<p>2. <strong>Vitamin D</strong> is a <strong>cytoplasmic receptor.</strong> All intracellular receptors are inherently nuclear receptors as they bind and get activated at the nucleus as mentioned above but they have two sites of primary action- cytoplasm and nucleus. </p>\n<p>3. While receptor tyrosine kinases have intrinsic tyrosine kinase activity, non-receptor tyrosine kinases have an external tyrosine kinase component that interacts with the receptor as and when required. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9913",
      "difficulty": "easy"
    },
    {
      "text": "Glucocorticoids do not have permissive action on which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Angiotensin"
        },
        {
          "id": 2,
          "text": "Adrenaline"
        },
        {
          "id": 3,
          "text": "Noradrenaline"
        },
        {
          "id": 4,
          "text": "Bradykinin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Glucocorticoids&nbsp;do not have permissive action on <strong>bradykinin</strong>. They inhibit inflammatory mediators such as histamine, bradykinin, and eicosanoids.&nbsp;</p>\n<p>Glucocorticoids possess <strong>permissive action</strong> on the <strong>vasoconstrictor</strong> effect of <strong>angiotensin</strong> and <strong>lipolytic</strong> action of <strong>adrenaline</strong> and <strong>noradrenaline</strong>. In the absence of glucocorticoids, these hormones have low activity but the presence enhances their activity several folds.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9914",
      "difficulty": "medium"
    },
    {
      "text": "A pregnant woman diagnosed with Cushing's syndrome does not want surgery and requests medical treatment. Which of the following drugs can be recommended?",
      "choices": [
        {
          "id": 1,
          "text": "Mifepristone"
        },
        {
          "id": 2,
          "text": "Flutamide"
        },
        {
          "id": 3,
          "text": "Finasteride"
        },
        {
          "id": 4,
          "text": "Metyrapone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Metyrapone</strong>&nbsp;can be recommended as it is <strong>approved</strong>&nbsp;in the treatment of&nbsp;<strong>pregnant </strong>women with<strong> Cushing's</strong> <strong>syndrome</strong>.&nbsp;It&nbsp;<strong>inhibits</strong> the <strong>synthesis </strong>of <strong>cortisol</strong>&nbsp;by&nbsp;inhibiting steroid 11 &beta;-hydroxylase reversibly.&nbsp;</p>\n<p>Cushing&rsquo;s syndrome (CS) is a manifestation of symptoms that are precipitated by <strong>excessive cortisol production.</strong> Transsphenoidal surgery, radiation, and pharmacotherapy constitute the standard treatment for tumor-related causes of CS (e.g. pituitary adenoma).</p>\n<p>The three main pharmacological approaches are:</p>\n<ul>\n<li>Cortisol synthesis inhibitors: Ketoconazole, metyrapone, mitotane, etomidate, aminoglutethimide</li>\n<li>ACTH secretion inhibitors: Cyproheptadine, pasireotide, octreotide, cabergoline</li>\n<li>Glucocorticoid receptor antagonist: Mifepristone</li>\n</ul>\n<p>Note: Metyrapone is also used to test the hypothalamic-pituitary feedback pathway in the diagnosis of Cushing syndrome.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9898",
      "difficulty": "medium"
    },
    {
      "text": "The enzyme A in the following image corresponds to?",
      "choices": [
        {
          "id": 1,
          "text": "17β-Hydroxysteroid dehydrogenase"
        },
        {
          "id": 2,
          "text": "3β-Hydroxysteroid dehydrogenase"
        },
        {
          "id": 3,
          "text": "11β-Hydroxysteroid dehydrogenase1"
        },
        {
          "id": 4,
          "text": "11β-Hydroxysteroid dehydrogenase2"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>\"<strong>A</strong>\" here corresponds to <strong>11-beta-HSD2</strong> (11&beta;-Hydroxysteroid dehydrogenase2). It converts active <strong>cortisol</strong> to inactive <strong>cortisone.</strong>&nbsp;</p>\n<p><strong>Cortisol</strong> is active and can bind to <strong>both glucocorticoids and mineralocorticoid receptors</strong> whereas cortisone is inactive and does not bind to either. The <strong>selective inactivation</strong> of cortisol is required in certain sites such as the <strong>distal nephron</strong> so that the specific autoregulatory responses to <strong>aldosterone</strong> can be achieved.</p>\n<p>Therefore, cortisol (active) is metabolized to cortisone (inactive) by <strong>11-beta-HSD2</strong> in the <strong>kidney,</strong> so as to protect renal mineralocorticoid receptors from cortisol binding.&nbsp;Some tissues, like the liver, can convert inactive cortisone back to active cortisol through an enzyme called <strong>11-beta-HSD1</strong> (\"<strong>B</strong>\" in the image).&nbsp;This completes the &ldquo;<strong>cortisone&ndash;cortisol shuttle</strong>&rdquo; because the kidney can inactivate cortisol where it is not needed and the liver can reactivate it afterward.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bb2fd6d0efba4d66b6788326ecc331d2x1280x1437.JPEG\" alt=\"Explanation Image\"><p><br />However, when circulating cortisol levels are very high, as in <strong>severe Cushing syndrome</strong>, they can overwhelm this protective mechanism, allowing cortisol to bind to and activate the mineralocorticoid receptor. This leads to <strong>volume expansion, hypertension, and hypokalemia</strong> often observed in hypercortisolism. A mutation of 11-beta-HSD2 also causes a similar clinical picture and is the reason for the <strong>syndrome of apparent mineralocorticoid excess</strong>.</p>\n<p>17&beta;-Hydroxysteroid dehydrogenase and&nbsp;3&beta;-Hydroxysteroid dehydrogenase are involved in the metabolism of sex steroids.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/ce85a543b090472f885a51539c8d76cc.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3537",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is a prodrug?",
      "choices": [
        {
          "id": 1,
          "text": "Prednisolone"
        },
        {
          "id": 2,
          "text": "Methylprednisolone"
        },
        {
          "id": 3,
          "text": "Hydrocortisone"
        },
        {
          "id": 4,
          "text": "Prednisone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Prednisone</strong> is a <strong>prodrug</strong>.</p>\n<p>It is a <strong>synthetic</strong> <strong>glucocorticoid</strong> that is biologically inert until converted via <strong>hepatic metabolism</strong>&nbsp;(11-beta HSD1) to the active component, <strong>prednisolone.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9916",
      "difficulty": "medium"
    },
    {
      "text": "A patient with moderate COVID-19 was started on a long-acting glucocorticoid. Which of the following drugs could it be?",
      "choices": [
        {
          "id": 1,
          "text": "Triamcinolone"
        },
        {
          "id": 2,
          "text": "Prednisolone"
        },
        {
          "id": 3,
          "text": "Dexamethasone"
        },
        {
          "id": 4,
          "text": "Hydrocortisone"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Dexamethasone</strong> is the <strong>longest acting glucocorticoid</strong>. Its t<sub>1/2</sub> is &gt;36 hours.</p><hr><h3>Related Pearl: Classification of Glucocorticoids</h3><p><strong>Short-acting</strong> (t<sub>1/2</sub> &lt; 12 hours)</p>\n<ul>\n<li>Hydrocortisone</li>\n</ul>\n<p><strong>Intermediate-acting</strong> (t<sub>1/2</sub>&nbsp;of 12-36 hours)</p>\n<ul>\n<li>Prednisolone</li>\n<li>Methylprednisolone</li>\n<li>Triamcinolone</li>\n<li>Deflazacort</li>\n</ul>\n<p><strong>Long-acting</strong> (t<sub>1/2</sub> &gt; 36 hours)</p>\n<ul>\n<li>Dexamethasone</li>\n<li>Betamethasone</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9920",
      "difficulty": "easy"
    },
    {
      "text": "Highest mineralocorticoid activity is seen with which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Aldosterone"
        },
        {
          "id": 2,
          "text": "DOCA"
        },
        {
          "id": 3,
          "text": "Fludrocortisone"
        },
        {
          "id": 4,
          "text": "Triamcinolone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The highest mineralocorticoid activity is seen with <strong>aldosterone.</strong></p>\n<p>However, it <strong>cannot be used clinically</strong>. The highest mineralocorticoid activity in a <strong>drug</strong> that is used <strong>clinically</strong> is <strong>fludrocortisone</strong>.&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Glucocorticoid activity</strong></td>\n<td><strong>Mineralocorticoid activity</strong></td>\n</tr>\n<tr>\n<td><strong>Short-acting glucocorticoids</strong></td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Cortisone</p>\n<p>Hydrocortisone</p>\n</td>\n<td>\n<p>0.8</p>\n<p>1</p>\n</td>\n<td>\n<p>0.8</p>\n<p>1</p>\n</td>\n</tr>\n<tr>\n<td><strong>Intermediate-acting&nbsp;glucocorticoids</strong></td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Prednisone-prednisolone</p>\n<p>Methylprednisolone</p>\n</td>\n<td>\n<p>4</p>\n<p>5</p>\n</td>\n<td>\n<p>0.8</p>\n<p>0.5</p>\n</td>\n</tr>\n<tr>\n<td><strong>Long-acting&nbsp;glucocorticoids</strong></td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Dexamethasone</p>\n<p>Betamethasone</p>\n</td>\n<td>\n<p>30</p>\n<p>30</p>\n</td>\n<td>\n<p>0</p>\n<p>0</p>\n</td>\n</tr>\n<tr>\n<td><strong>Mineralocorticoids</strong></td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Deoxycorticosterone (DOCA)</p>\n<p>Fludrocortisone</p>\n<p>Aldosterone</p>\n</td>\n<td>\n<p>0.2</p>\n<p>15</p>\n<p>0</p>\n</td>\n<td>\n<p>100</p>\n<p>150</p>\n<p>200-500</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Activity of corticosteroids</h3><p><strong>Highest mineralocorticoid </strong>activity is seen with <strong>aldosterone</strong>.</p>\n<p>Highest mineralocorticoid activity in a drug that is <strong>clinically used</strong> is seen with <strong>fludrocortisone</strong>&nbsp;(aldosterone cannot be used clinically).</p>\n<p><strong>Least </strong>mineralocorticoid activity is seen with <strong>methylprednisolone</strong>.</p>\n<p>&nbsp;</p>\n<p><strong>Highest glucocorticoid</strong> activity is seen with <strong>dexamethasone </strong>and<strong> betamethasone</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9918",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a mineralocorticoid receptor antagonist?",
      "choices": [
        {
          "id": 1,
          "text": "Spironolactone"
        },
        {
          "id": 2,
          "text": "Eplerenone"
        },
        {
          "id": 3,
          "text": "Drospirenone"
        },
        {
          "id": 4,
          "text": "Metyrapone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Metyrapone</strong> is <strong>not</strong> a mineralocorticoid receptor antagonist.</p>\n<p>It is a selective inhibitor of&nbsp;<strong>11&beta;-hydroxylase&nbsp;</strong>and thereby reduces&nbsp;cortisol and <strong>corticosterone synthesis</strong>.</p>\n<p>Options A and B - Spironolactone and eplerenone are <strong>aldosterone antagonist</strong> that is used in hypertension and chronic CHF for reversing the effects of aldosterone</p>\n<p>Option C - Drospirenone is a 4th generation <strong>progestin</strong> used as an oral contraceptive having <strong>mineralocorticoid antagonist</strong> action</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9947",
      "difficulty": "medium"
    },
    {
      "text": "A woman diagnosed with Sheehan's syndrome is planned for the initiation of hormone replacement. Glucocorticoids should be administered prior to thyroxine supplementation due to what concern?",
      "choices": [
        {
          "id": 1,
          "text": "Interference in absorption of glucocorticoids"
        },
        {
          "id": 2,
          "text": "Precipitation acute adrenal insufficiency"
        },
        {
          "id": 3,
          "text": "Decrease in the metabolism of glucocorticoids"
        },
        {
          "id": 4,
          "text": "Suppression the HPA axis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Glucocorticoids</strong> are administered <strong>before</strong> initiating treatment with&nbsp;<strong>thyroid hormones</strong>&nbsp;as administration of thyroxine can <strong>precipitate acute adrenal insufficiency.</strong></p>\n<p>In the case of combined adrenal insufficiency and hypothyroidism, as in <strong>panhypopituitarism</strong> (due to surgery or <strong>Sheehan's</strong> syndrome), adrenal insufficiency is generally treated first. This is because giving thyroxine first can <strong>enhance cortisol clearance</strong> and precipitate an adrenal crisis. Also, <strong>levothyroxine</strong> increases the basal metabolic rate (BMR) leading to an&nbsp;<strong>increased requirement of cortisol,</strong> which if not met can also precipitate an adrenal crisis.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3535",
      "difficulty": "medium"
    },
    {
      "text": "A pregnant woman came for routine antenatal screening. During prenatal testing, the fetus was suspected to have congenital adrenal hyperplasia. What is the drug of choice for treating the fetus in-utero?",
      "choices": [
        {
          "id": 1,
          "text": "Dexamethasone"
        },
        {
          "id": 2,
          "text": "Betamethasone"
        },
        {
          "id": 3,
          "text": "Hydrocortisone"
        },
        {
          "id": 4,
          "text": "Prednisolone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>drug of choice</strong> for treating the <strong>fetus</strong> in-utero when suspected of having<strong> congenital adrenal hyperplasia</strong> is <strong>dexamethasone.</strong></p>\n<p>Dexamethasone readily <strong>crosses the placenta </strong>and suppresses the secretion of steroids and androgens by fetal adrenal glands. If started by 6 weeks of gestation, it reduces the virilization of external genitalia in affected females.</p>\n<p><strong>Chorionic villus biopsy</strong> is then performed to determine the sex and the genotype of the fetus and therapy is only continued if the fetus is an <strong>affected female.</strong></p>\n<p>This is not widely accepted currently due to insufficient data on long-term risks especially in unaffected females and males who derive no benefit from the treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9950",
      "difficulty": "medium"
    },
    {
      "text": "A patient is started on hormone replacement for chronic adrenal insufficiency. What is the replacement dose of hydrocortisone that has to be given (in mg/day)?",
      "choices": [
        {
          "id": 1,
          "text": "10"
        },
        {
          "id": 2,
          "text": "15"
        },
        {
          "id": 3,
          "text": "20"
        },
        {
          "id": 4,
          "text": "5"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The replacement dose of hydrocortisone for <strong>chronic adrenal insufficiency</strong> is <strong>20 mg/day.</strong></p>\n<p>The treatment of chronic adrenal insufficiency (<strong>not in crisis</strong>) requires glucocorticoid replacement at a dose that replaces the physiologic daily cortisol production. This is achieved by administering an oral replacement dose of <strong>15-25mg</strong> <strong>Hydrocortisone.</strong> <br />A <strong>midpoint dose of 20mg</strong> is given in 2-3 divided doses: <strong>10mg + 5mg + 5mg</strong>. <br />A higher morning dose is given at 8:30 am (usually 1/2 to 2/3 of the total dose). The next dose is given at 1:30 pm and in the evening (4:30-5:00 pm). This is to follow the normal circadian rhythm. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9893",
      "difficulty": "medium"
    },
    {
      "text": "A pregnant woman at 33 weeks of gestation presents to your antenatal clinic with preterm labour.  Which corticosteroid will you administer for stimulation of fetal lung maturation?",
      "choices": [
        {
          "id": 1,
          "text": "Hydrocortisone"
        },
        {
          "id": 2,
          "text": "Triamcinolone"
        },
        {
          "id": 3,
          "text": "Methylprednisolone"
        },
        {
          "id": 4,
          "text": "Betamethasone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Betamethasone</strong> is indicated for the stimulation of <strong>fetal lung maturation </strong>in<strong> preterm labor.</strong></p>\n<p>As compared to cortisol, betamethasone <strong>binds to maternal proteins less</strong> and has <strong>less placental metabolism</strong>. This allows increased transfer to the fetus. Additionally, infants exposed to betamethasone are less likely to require postnatal resuscitation.&nbsp;2 doses of 12 mg each are administered 18-24 hours apart when the delivery is anticipated before 34 weeks of gestation.</p>\n<p><strong>Dexamethasone </strong>is&nbsp;another long-acting glucocorticoid that can be given. It has benefits such as <strong>less risk of intraventricular hemorrhage</strong> and a shorter length of stay in the NICU.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9900",
      "difficulty": "easy"
    },
    {
      "text": "A patient with chronic adrenal insufficiency is on long term corticosteroid therapy. Which of the following side effects is he unlikely to experience?",
      "choices": [
        {
          "id": 1,
          "text": "Muscular hypertrophy"
        },
        {
          "id": 2,
          "text": "Peptic ulceration"
        },
        {
          "id": 3,
          "text": "Psychosis"
        },
        {
          "id": 4,
          "text": "Hypertension"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Corticosteroid therapy does <strong>not</strong> cause <strong>muscular hypertrophy</strong> and the patient is unlikely to experience it as a side effect.</p>\n<p><strong>Excess glucocorticoid</strong> activity results in&nbsp;<strong>muscle wasting and myopathy </strong>while <strong>excess mineralocorticoid activity </strong>results in hypokalemia and causes<strong> muscle weakness.</strong></p>\n<p>Options B and C:&nbsp;<strong>Peptic ulceration </strong>and<strong> psychosis</strong> are known adverse effects of corticosteroids.</p>\n<p>Option D: Glucocorticoids with some mineralocorticoid activity will result in sodium and water retention and may cause <strong>hypertension.</strong></p><hr><h3>Related Pearl: Side effects of Corticosteroids: mnemonic \"CORTICOSTEROIDS\"</h3><p>The mnemonic is \"<strong>CORTICOSTEROIDS</strong>\"</p>\n<p><strong>C</strong> - Cushing&rsquo;s syndrome</p>\n<p><strong>O</strong> - Osteoporosis</p>\n<p><strong>R</strong> - Retardation of growth</p>\n<p><strong>T</strong> - Thin skin and easy bruisability</p>\n<p><strong>I</strong> - Infections and immunosuppression</p>\n<p><strong>C</strong> - Cataract</p>\n<p><strong>O</strong> - Oedema</p>\n<p><strong>S</strong> - Suppression of HPA axis</p>\n<p><strong>T</strong> - Thinning and ulceration of gastric mucosa</p>\n<p><strong>E</strong> - Emotional disturbance</p>\n<p><strong>R</strong> - Rise in BP</p>\n<p><strong>O</strong> - Others fatal abnormalities like hypokalemia</p>\n<p><strong>I</strong> - Increase in hair growth (hirsutism)</p>\n<p><strong>D</strong> - Diabetes mellitus precipitation</p>\n<p><strong>S</strong> - Striae</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9924",
      "difficulty": "medium"
    },
    {
      "text": "You are planning to add oral steroids to manage a case of severe asthma. Presence of which of the following comorbidities is not a relative contraindication for starting the medication?",
      "choices": [
        {
          "id": 1,
          "text": "Diabetes mellitus"
        },
        {
          "id": 2,
          "text": "Hypertension"
        },
        {
          "id": 3,
          "text": "Eczematous skin disease"
        },
        {
          "id": 4,
          "text": "Peptic ulcer disease"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Eczematous skin diseases</strong> are <strong>not</strong> a contraindication for the use of oral corticosteroids. In fact, they are&nbsp;highly effective and are indicated in this condition.</p>\n<p>All the <strong>contraindications to steroids are relative</strong> because of the life-saving nature of steroids.</p>\n<p>Risk-benefit should be assessed cautiously when initiating steroids in the following conditions:</p>\n<ul>\n<li><strong>Diabetes mellitus</strong></li>\n<li><strong>Hypertension</strong></li>\n<li><strong>Peptic ulcer</strong></li>\n<li>Viral and fungal infections</li>\n<li>Tuberculosis and other infections</li>\n<li>Osteoporosis</li>\n<li>Herpes simplex keratitis</li>\n<li>Epilepsy</li>\n<li>CHF</li>\n<li>Renal failure</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9926",
      "difficulty": "medium"
    },
    {
      "text": "A 54-year-old woman is being evaluated for chronic back pain. She mentions that she had been on corticosteroids for asthma since childhood. Which of the following actions of the drug would not cause her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of gonadal steroidal hormones"
        },
        {
          "id": 2,
          "text": "Reduced gastrointestinal absorption of calcium"
        },
        {
          "id": 3,
          "text": "Suppressive action on osteoblasts"
        },
        {
          "id": 4,
          "text": "Inhibition of action of osteoclasts"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Chronic back pain</strong> following long term <strong>corticosteroid</strong> therapy is suggestive of <strong>osteoporosis</strong>.&nbsp;Glucocorticoids <strong>do not inhibit</strong> of the action of <strong>osteoclasts</strong>.</p>\n<p>It causes<strong> stimulation of osteoclasts</strong> and <strong>increases bone resorption.</strong></p>\n<p>Mechanism of glucocorticoids induced osteoporosis:</p>\n<ul>\n<li>Inhibition of gonadal steroidal hormones</li>\n<li>Reduced gastrointestinal absorption of calcium</li>\n<li>Secondary effect of decreased calcium absorption: increased parathyroid hormone leading to further resorption</li>\n<li>Suppressive action on osteoblasts</li>\n<li>Stimulation of osteoclasts</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9929",
      "difficulty": "medium"
    },
    {
      "text": "Osteonecrosis following glucocorticoid therapy is most commonly associated with which site?",
      "choices": [
        {
          "id": 1,
          "text": "Femoral head"
        },
        {
          "id": 2,
          "text": "Distal femur"
        },
        {
          "id": 3,
          "text": "Jaw bone"
        },
        {
          "id": 4,
          "text": "Humeral head"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>femoral head</strong> is the most frequently affected site by&nbsp;<strong>osteonecrosis</strong> due to <strong>glucocorticoid</strong> therapy.</p>\n<p>The earliest symptoms are joint pain and stiffness. When patients on steroid therapy develop hip, shoulder or knee pain, osteonecrosis must&nbsp;be considered and ruled out.</p>\n<p>Options B and D - It can also affect the distal femur and humeral head&nbsp;</p>\n<p>Option C -&nbsp;<strong>Osteonecrosis of the jaw</strong> is associated with the use of<strong> bisphosphonates&nbsp;</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9937",
      "difficulty": "medium"
    },
    {
      "text": "A patient with Cushing’s syndrome has very high levels of ACTH. Which of the following is a CRH preparation that can be used to determine if it is a pituitary source or an ectopic source?",
      "choices": [
        {
          "id": 1,
          "text": "Gonadorelin"
        },
        {
          "id": 2,
          "text": "Corticorelin"
        },
        {
          "id": 3,
          "text": "Ganirelix"
        },
        {
          "id": 4,
          "text": "Cosyntropin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Corticorelin</strong> is a corticotrophin-releasing hormone (<strong>CRH</strong>) preparation used in CRH stimulation test which helps to <strong>differentiate</strong> between a <strong>pituitary source and an ectopic</strong> source for <strong>ACTH-dependent hypercortisolism</strong>.&nbsp;</p>\n<p>Pituitary tumors tend to be sensitive to CRH stimulation and responds with a rise in cortisol while ectopic tumors do not usually respond.&nbsp;Ectopic sources of ACTH include carcinoid, medullary thyroid carcinoma, and pheochromocytoma.</p>\n<p>It can also be used to test the HPA axis.</p>\n<p>Option A - Gonadorelin is a <strong>recombinant GnRH.</strong></p>\n<p>Option C - Ganirelix is a <strong>GnRH antagonist.</strong></p>\n<p>Option D - Cosyntropin is a synthetic preparation of <strong>ACTH.</strong></p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9903",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a steroid receptor antagonist that can be given to a patient with Cushing’s syndrome due to ectopic ACTH?",
      "choices": [
        {
          "id": 1,
          "text": "Ketoconazole"
        },
        {
          "id": 2,
          "text": "Metyrapone"
        },
        {
          "id": 3,
          "text": "Mifepristone"
        },
        {
          "id": 4,
          "text": "Aminoglutethimide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Mifepristone </strong>is a <strong>steroid receptor antagonist </strong>that can be used in <strong>Cushing&rsquo;s syndrome.</strong></p>\n<p>It is used in Cushing&rsquo;s syndrome especially in inoperable cases with ectopic ACTH secretion or adrenal carcinoma.</p>\n<p>Options A, B, and D - Ketoconazole, metyrapone, and&nbsp;aminoglutethimide&nbsp;reduce steroid synthesis by enzyme inhibition.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9946",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following intravenous anaesthetics can be used for acute control of hypercortisolism?",
      "choices": [
        {
          "id": 1,
          "text": "Thiopentone"
        },
        {
          "id": 2,
          "text": "Propofol"
        },
        {
          "id": 3,
          "text": "Ketamine"
        },
        {
          "id": 4,
          "text": "Etomidate"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The intravenous&nbsp;anesthetic that can be used for acute control of hypercortisolism is<strong> etomidate</strong>.</p>\n<p>Etomidate at sub-hypnotic doses <strong>inhibits cortisol secretion </strong>by selectively <strong>inhibiting</strong> <strong>11-beta-hydroxylase</strong> activity.<strong>&nbsp;</strong></p>\n<p>It is used off-label to treat hypercortisolism when <strong>rapid control</strong> is needed and the patient is <strong>not able to take oral </strong>medication.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9949",
      "difficulty": "medium"
    },
    {
      "text": "A patient is diagnosed with inoperable adrenocortical carcinoma and needs medical adrenalectomy. Which of the following drugs could be used for him?",
      "choices": [
        {
          "id": 1,
          "text": "Mitotane"
        },
        {
          "id": 2,
          "text": "Methotrexate"
        },
        {
          "id": 3,
          "text": "Doxorubicin"
        },
        {
          "id": 4,
          "text": "5-Fluorouracil"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Mitotane</strong>&nbsp;is used for <strong>medical adrenalectomy</strong> in this patient.</p>\n<p>It has a <strong>non-selective toxic action </strong>on the <strong>adrenal cortex.&nbsp;</strong>It causes suppression of adrenal cortex hormone secretion comparable to that of adrenalectomy.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9942",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following antifungal drugs can be used in the treatment of a patient with Cushing syndrome?",
      "choices": [
        {
          "id": 1,
          "text": "Ketoconazole"
        },
        {
          "id": 2,
          "text": "Fluconazole"
        },
        {
          "id": 3,
          "text": "Itraconazole"
        },
        {
          "id": 4,
          "text": "Miconazole"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ketoconazole</strong> can be used in the treatment of <strong>Cushing syndrome</strong> for symptomatic control.</p>\n<p>It is a non-selective <strong>inhibitor</strong> of adrenal and gonadal <strong>steroid synthesis</strong>. These actions are more apparent at higher doses than those used for fungal infections.</p><p>The FDA recently approved the drug <strong>Osilodrostat</strong>, an <strong>oral 11&beta;-hydroxylase inhibitor</strong> for adults with <strong>Cushing&rsquo;s disease</strong> who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9944",
      "difficulty": "easy"
    }
  ]
}